★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Gilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Gilead Sciences, Inc. is a U.S. biopharmaceutical company with Q1 2026 product sales concentrated in HIV (~72%), plus oncology, liver disease, Veklury and other mature products. The core HIV moat combines prescriber/patient inertia around Biktarvy, time-bounded exclusivity now supported by 2036 Biktarvy settlement timing for certain generics, and long-acting prevention expansion through Yeztugo. Oncology moats are more operational: CAR-T treatment-center logistics, manufacturing know-how, and pipeline extension through Arcellx/anito-cel and ADC investments. Liver disease benefits from Livdelzi momentum in PBC. Key erosion pressures are Medicare negotiation, patent cliffs, payer rebates, modality competition, and oncology execution risk.
Primary segment
HIV
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
5 segments · 8 tags
Updated 2026-07-01
Segments
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Revenue
72.4%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Oncology (Cell Therapy + Trodelvy)
Oncology therapeutics focused on CAR T-cell therapy and antibody-drug conjugates (ADC)
Revenue
11.6%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Liver Disease
Liver disease therapeutics (viral hepatitis and cholestatic liver disease)
Revenue
11%
Structure
Oligopoly
Pricing
weak
Share
—
Peers
Veklury (Remdesivir)
Hospital antiviral therapies for COVID-19
Revenue
2.1%
Structure
Competitive
Pricing
weak
Share
—
Peers
Other Products
Other specialty and legacy therapeutics (e.g., antifungals, PAH, other mature products)
Revenue
2.8%
Structure
Competitive
Pricing
weak
Share
—
Peers
Moat Claims
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Revenue_share computed from Q1 2026 product sales in the earnings release: HIV $5,032m / total product sales $6,946m. Current proxy supports HIV leadership but does not provide a numeric Biktarvy treatment market share, so the prior share estimate was removed.
Habit Default
Demand
Habit Default
Strength
Durability
Confidence
Evidence
Biktarvy's scale, Yeztugo's launch, and Gilead's HIV prevention coverage reinforce prescriber default behavior and patient persistence within Gilead's HIV portfolio.
Habit Default moat: definition, examples, and stocks
Erosion risks
- Competitor long-acting regimens (e.g., injectable treatment/PrEP) gaining share
- Generic entry after patent expiry
- Payer/formulary actions increasing rebates or steering to alternatives
Leading indicators
- Biktarvy and overall HIV portfolio market share trends
- Net realized price and gross-to-net deductions
- Guideline placement and new-start share
Counterarguments
- High-performing alternatives (including long-acting options) can shift prescriber behavior
- Formulary restrictions can override prescriber preference
Switching Costs General
Demand
Switching Costs General
Strength
Durability
Confidence
Evidence
Once patients are virologically suppressed, regimen switching introduces adherence/tolerability risk and workflow friction; this supports persistence in chronic HIV therapy.
Switching Costs General moat: definition, examples, and stocks
Erosion risks
- Rapid feature parity in competing regimens
- Safety signals or label changes reducing confidence
- Improved cross-regimen switching support reducing friction
Leading indicators
- Discontinuation/churn rates for core regimens
- Share of switches away from Biktarvy/Descovy
- Adherence and persistence metrics where disclosed
Counterarguments
- Switching can be relatively easy when clinical differences narrow
- Patients can be moved for price reasons if outcomes are comparable
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents and regulatory exclusivities (and related litigation/settlements) delay generic entry for major HIV products, though timing is finite and litigated.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Adverse court rulings or settlements enabling earlier generic entry
- Patent expirations and loss of exclusivity cycles
- Regulatory actions affecting exclusivity or pricing
Leading indicators
- Key patent litigation milestones and outcomes
- Patent expiry timelines for core HIV products
- Generic or authorized-generic launches
Counterarguments
- Strong brands can still see rapid erosion when generics enter
- Competitors can innovate around patents with new mechanisms or delivery
Oncology (Cell Therapy + Trodelvy)
Oncology therapeutics focused on CAR T-cell therapy and antibody-drug conjugates (ADC)
Revenue_share computed from Q1 2026 product sales in the earnings release: Cell Therapy $407m plus Trodelvy $402m / total product sales $6,946m. Trodelvy grew 37% year over year, while cell therapy sales fell 12% from competitive headwinds.
Service Field Network
Supply
Service Field Network
Strength
Durability
Confidence
Evidence
CAR-T delivery depends on a coordinated network of apheresis collection sites, logistics, and certified hospitals; execution and relationships create barriers for newer entrants.
Service Field Network moat: definition, examples, and stocks
Erosion risks
- Competitors expanding their own treatment-center networks
- Safety concerns reducing utilization
- Reimbursement tightening or site-of-care shifts
Leading indicators
- Number of certified treatment centers and throughput
- Turnaround time from collection to infusion
- Patient volumes and new indication approvals
Counterarguments
- Networks can be replicated over time by well-funded competitors
- Alternative modalities (e.g., bispecific antibodies) can bypass CAR-T logistics
Capex Knowhow Scale
Supply
Capex Knowhow Scale
Strength
Durability
Confidence
Evidence
Scaled cell therapy manufacturing know-how (speed, reliability) is a differentiator; faster turnaround can expand treatable patients and clinician preference.
Capex Knowhow Scale moat: definition, examples, and stocks
Erosion risks
- Manufacturing disruptions or capacity constraints
- Process improvements adopted by competitors
- Technology shifts to off-the-shelf or in-vivo approaches
Leading indicators
- Turnaround time and capacity expansion disclosures
- Regulatory inspection outcomes for manufacturing sites
- Adoption of next-generation products/indications
Counterarguments
- Turnaround time alone may not determine choice if efficacy/safety differs
- Next-gen therapies could reset learning curves and reduce incumbency advantages
Compliance Advantage
Legal
Compliance Advantage
Strength
Durability
Confidence
Evidence
REMS-driven certification and side-effect management requirements create operational barriers and reinforce established center workflows.
Compliance Advantage moat: definition, examples, and stocks
Erosion risks
- Regulatory changes reducing certification burdens
- Standardization of CAR-T procedures across providers
- Competitors providing superior center-support programs
Leading indicators
- Changes to REMS/label requirements
- Center participation and certification expansion
- Coverage policy changes by major payers
Counterarguments
- Certification requirements can become table-stakes across the industry
- Superior clinical outcomes can overcome operational friction
Liver Disease
Liver disease therapeutics (viral hepatitis and cholestatic liver disease)
Revenue_share computed from Q1 2026 product sales in the earnings release: Liver Disease $767m / total product sales $6,946m. Q1 growth reflected higher Livdelzi demand offset by inventory dynamics and lower HCV sales.
Regulated Standards Pipe
Legal
Regulated Standards Pipe
Strength
Durability
Confidence
Evidence
Regulatory approvals and clinical data (including accelerated approvals) support differentiated positions in select liver disease indications.
Regulated Standards Pipe moat: definition, examples, and stocks
Erosion risks
- Competition and price erosion in mature viral hepatitis markets
- Regulatory setbacks for pipeline candidates
- Payer restrictions favoring lowest-cost therapies
Leading indicators
- Livdelzi uptake and payer coverage
- HBV/HDV demand trends
- Late-stage liver disease pipeline progress
Counterarguments
- Several liver disease categories are mature with many alternatives
- Effectiveness parity can make price the primary decision factor
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents and settlement agreements around TAF support exclusivity defense for products including Vemlidy, but this protection is time-bounded.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Loss of exclusivity for core components
- Generic/authorized-generic launches
- Competitor innovation in HBV/HDV/PBC
Leading indicators
- Key patent expiry and litigation milestones
- Net price trajectory for Vemlidy and other liver products
- Competitor trial readouts and approvals
Counterarguments
- IP has a finite timeline; erosion can be rapid post-LOE
- Novel competitors can leapfrog legacy mechanisms
Veklury (Remdesivir)
Hospital antiviral therapies for COVID-19
Revenue_share computed from Q1 2026 product sales in the earnings release: Veklury $144m / total product sales $6,946m. Veklury sales fell 52% year over year due to lower COVID-19 hospitalization rates.
Regulated Standards Pipe
Legal
Regulated Standards Pipe
Strength
Durability
Confidence
Evidence
Regulatory exclusivities and approved labeling support use, but demand is highly sensitive to hospitalization rates and competing therapies.
Regulated Standards Pipe moat: definition, examples, and stocks
Erosion risks
- Declining COVID-19 hospitalization rates
- Guideline shifts and competing antivirals/therapeutics
- Loss of exclusivity and generic entry
Leading indicators
- COVID-19 hospitalization trends
- Treatment guideline updates
- Competitive launches and trial results for next-gen antivirals
Counterarguments
- Market demand is episodic and can contract rapidly
- Hospital procurement can switch based on protocols and price
Other Products
Other specialty and legacy therapeutics (e.g., antifungals, PAH, other mature products)
Revenue_share computed as residual Q1 2026 product sales: total product sales $6,946m less HIV, Oncology, Liver Disease and Veklury = $194m.
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Certain niche hospital products benefit from clinician familiarity and formulation differentiation, but many are mature and exposed to substitution.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Generic competition and price erosion
- Shifts to alternative therapies
- Portfolio rationalization/discontinuations
Leading indicators
- Volume and realized price trends for key legacy products
- Generic entries and substitution rates
- Regulatory or safety updates affecting prescribing
Counterarguments
- In mature categories, procurement often selects lowest-cost alternatives
- Formulation differentiation may not prevent share loss when alternatives are adequate
Evidence
Biktarvy is the most-prescribed HIV treatment regimen
Proxy statement describes Biktarvy as the most-prescribed HIV regimen with over one million users and notes Yeztugo reached about 90% U.S. payer coverage by year-end 2025.
supported by the successful launch of Yeztugo
Current-quarter release ties 10% HIV growth to higher HIV sales and the successful Yeztugo launch.
efficacy, safety, tolerability
The 10-K frames competition around clinical outcomes and tolerability, consistent with switching frictions.
Patents and other proprietary rights are very important
The 10-K emphasizes reliance on patents and proprietary rights to protect key products.
no generic entry by the parties
The 10-K discloses settlement agreements with generic manufacturers that delay U.S. Biktarvy generic entry for those parties until 2036, subject to acceleration provisions.
Showing 5 of 13 sources.
Risks & Indicators
Erosion risks
- Competitor long-acting regimens (e.g., injectable treatment/PrEP) gaining share
- Generic entry after patent expiry
- Payer/formulary actions increasing rebates or steering to alternatives
- Rapid feature parity in competing regimens
- Safety signals or label changes reducing confidence
- Improved cross-regimen switching support reducing friction
Leading indicators
- Biktarvy and overall HIV portfolio market share trends
- Net realized price and gross-to-net deductions
- Guideline placement and new-start share
- Discontinuation/churn rates for core regimens
- Share of switches away from Biktarvy/Descovy
- Adherence and persistence metrics where disclosed
Research GILD elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.